Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19()

The outcome of the SARS-CoV-2 (COVID-19) infection fundamentally affects the lung field, causing ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS). This process is an inflammatory picture, involving an NLRP3 INFLAMOSOME-triggered cytokine storm, the main player in alveolar destruction. IL-1 beta stands out...

Descripción completa

Detalles Bibliográficos
Autores principales: Muñoz-Jiménez, Alejandro, Rubio-Romero, Esteban, Fuente, José Luis Marenco de la
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. 2021
Materias:
Special Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8041148/
https://www.ncbi.nlm.nih.gov/pubmed/32482538
http://dx.doi.org/10.1016/j.reumae.2020.04.012
Descripción
Sumario:The outcome of the SARS-CoV-2 (COVID-19) infection fundamentally affects the lung field, causing ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS). This process is an inflammatory picture, involving an NLRP3 INFLAMOSOME-triggered cytokine storm, the main player in alveolar destruction. IL-1 beta stands out among the cytokines that are triggered in this picture. ANAKINRA is a potent biological drug, capable of blocking this IL 1 beta. We propose its use in controlling ARDS secondary to COVID-19 infection.

Ejemplares similares